Peptides having reduced toxicity that stimulate cholesterol efflux
Abstract
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimers Disease or frontotemporal dementia.
- Inventors:
- Issue Date:
- Research Org.:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Org.:
- USDOE; National Institutes of Health (NIH)
- OSTI Identifier:
- 1840354
- Patent Number(s):
- 11091529
- Application Number:
- 15/511,623
- Assignee:
- The Regents of the University of California (Oakland, CA)
- Patent Classifications (CPCs):
-
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
- DOE Contract Number:
- AC02-05CH11231; HL085791
- Resource Type:
- Patent
- Resource Relation:
- Patent File Date: 09/14/2015
- Country of Publication:
- United States
- Language:
- English
Citation Formats
Bielicki, John K., and Johansson, Jan. Peptides having reduced toxicity that stimulate cholesterol efflux. United States: N. p., 2021.
Web.
Bielicki, John K., & Johansson, Jan. Peptides having reduced toxicity that stimulate cholesterol efflux. United States.
Bielicki, John K., and Johansson, Jan. Tue .
"Peptides having reduced toxicity that stimulate cholesterol efflux". United States. https://www.osti.gov/servlets/purl/1840354.
@article{osti_1840354,
title = {Peptides having reduced toxicity that stimulate cholesterol efflux},
author = {Bielicki, John K. and Johansson, Jan},
abstractNote = {The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimers Disease or frontotemporal dementia.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2021},
month = {8}
}
Works referenced in this record:
Prevention and treatment of restenosis by local administration of drug
patent, February 2012
- Bisgaier, Charles L.; Shah, Prediman K.; Kaul, Sanjay
- US Patent Document 8,119,590
Peptides Having Reduced Toxicity Thar Stimulate Cholesterol Efflux
patent-application, September 2014
- Bielicki, John K.; Johansson, Jan; Danho, Waleed
- US Patent Application 14/216749; 20140287994
Peptide mediators of cholesterol efflux
patent, April 2013
- Bielicki, John K.; Johansson, Jan
- US Patent Document 8,415,293
Helical synthetic peptides that stimulate cellular cholesterol efflux
patent-application, September 2005
- Bielicki, John K.; Natarajan, Pradeep
- US Patent Application 11/014187; 20050202532
Potent and Selective Mediators of Cholesterol Efflux
patent-application, December 2012
- Bielicki, John K.; Johansson, Jan
- US Patent Application 12/519116; 20120329703